PA
PDYN icon

PharVision Advisers’s Palladyne AI PDYN Stock Holding History

PharVision Advisers’s Portfolio PDYN Stock Details PDYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-44,149
Closed -$188K – 671
2025
Q4 		$188K Buy
44,149
+26,064
+144% +$175K 0.1% 583
2025
Q3 		$155K Buy
+18,085
New +$150K 0.09% 565

Other funds holding PDYN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TMC
Themes Management Co Greenwich, Connecticut $162M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PharVision Advisers's PDYN Position: Q1 2026 in Review

PharVision Advisers sold out of Palladyne AI (PDYN) in Q1 2026, closing a stake of 44,149 shares — an estimated $188K sold.

PharVision Advisers first reported a position in PDYN in Q3 2025 and held it in 2 quarters. The position peaked at $188K in Q4 2025. 118 funds tracked by Wall St. Rank hold PDYN as of Q1 2026.

  • PharVision Advisers reported no remaining Palladyne AI position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 44,149 Palladyne AI shares in Q1 2026, an estimated $188K.
  • PharVision Advisers first reported a position in Palladyne AI in Q3 2025 and held it in 2 quarters.
  • PharVision Advisers's Palladyne AI position peaked at $188K in Q4 2025.
  • 118 funds tracked by Wall St. Rank held Palladyne AI as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.